The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new framework to spur the development of therapies for ultra-rare ...

This deal adds two more siRNA candidates to GSK’s pipeline, which is expanding as the company looks to offset the impact of ...

Beren Therapeutics has received the US (FDA acceptance to review its NDA for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset NPC.

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing ...

We’re proud to share that EMBOCAPS® has once again been awarded the EcoVadis Gold rating, following last year’s recognition.

Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.

Three new members could join Novo’s council, which largely consists of recent appointees following a restructure in October ...

AstraZeneca has secured approval in the US for Calquence plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with CLL and SLL in the first-line setting.

The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.

Roche has obtained acceptance from the US FDA for its NDA submitted for giredestrant, an oral therapy, along with everolimus to treat breast cancer.

Anton Paar has announced the launch of the Litesizer DLS 301, the latest addition to its established Litesizer family.

Analysis by WHO estimates that 6.2 million lives could be saved if next-generation vaccines are used through to 2050.